Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Richmond, Australia Clinical Trials

A listing of Richmond, Australia clinical trials actively recruiting patients volunteers.

RESULTS

Found (37) clinical trials

Study to Assess the Patterns of Use of REKOVELLE in Na ve Women Undergoing In Vitro Fertilisation or Intracytoplasmic Sperm Injection Procedures

The purpose of this study is to monitor the use in routine clinical practice of REKOVELLE. This study will collect information from patients who never underwent previous in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) treatments for up to three consecutive treatment cycles. The ovarian stimulation protocol with REKOVELLE, ...

Phase N/A

0.99 miles

Learn More »

A Study of GDC-9545 in Postmenopausal Women With Stage I-III Operable Estrogen Receptor-Positive Breast Cancer

This study will evaluate the pharmacodynamics, pharmacokinetics, safety, and biologic activity of GDC-9545 in participants with Stage I-III operable estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, untreated breast cancer.

Phase

1.07 miles

Learn More »

Circulating Tumour DNA as a Marker of Residual Disease & Response to Adjuvant Chemotherapy in Stage I-IV Ovarian Cancer

This is a prospective,multi-centre study involving serial blood collections from 100 stage I-IV debulked (or to be debulked in the case of neoadjuvant chemotherapy) high grade serous, endometrioid and clear cell ovarian, fallopian tube and primary peritoneal cancer patients (EOC) or ovarian carcinosarcoma planned to receive adjuvant chemotherapy. Tumour samples ...

Phase N/A

1.07 miles

Learn More »

EXamining PErsonalised Radiation Therapy for Low-risk Early Breast Cancer

Radiation therapy (RT) after breast conserving surgery to improve local control and survival is the current standard of care for patients with early breast cancer. However, breast cancer is a heterogeneous disease, and the absolute benefit of RT in individual patients varies substantially. Thus, a pressing priority in contemporary breast ...

Phase N/A

1.07 miles

Learn More »

Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

Vasomotor symptoms (VMS) are significant in postmenopausal women with the most effective medications for relief being hormonal preparations. Non-hormonal medications have demonstrated efficacy but at a far lower level than estrogen replacement therapy. For women with a history of breast cancer, hormone replacement therapy is often contraindicated and is not ...

Phase

1.08 miles

Learn More »

Post-Operative Pain Management in Patients Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata

Post operative Pain Management in Paitents Undergoing Uterine Artery Embolisation for Symptomatic Leiomyomata Protocol (Ver 2.1) 1.1 Research Question Does pre emptive morphine dosing help reduce acute post operative pain (as expressed on a visual analogue scale, VAS) and/or post operative opioid use in patients undergoing uterine artery embolisation? 2.1 ...

Phase N/A

1.08 miles

Learn More »

A clinical trial seeking patients for a research study for the treatment of Pregnancy, Mental illness

The desire to reproduce is both a powerful urge and a basic human right for women regardless of mental health status. Deinstitutionalised treatment for mental illness, better pharmacotherapies, and generally higher expectations for a normal quality of life have the potential to raise the incidence of pregnancy in women with ...

Phase N/A

1.08 miles

Learn More »

Selective Estrogen Receptor Modulators for Women of Child-bearing Age With Schizophrenia

Estrogen is hypothesised to be protective for women against early onset of severe symptoms of schizophrenia (Hafner, 1991; Seeman, 1992). This 'estrogen hypothesis' was derived from epidemiological, clinical and animal studies. Following the results of such studies, the investigators conducted a study (Kulkarni et al 1996) in which a group ...

Phase

1.08 miles

Learn More »

BEACON - Targeting the C1 Subtype of High Grade Serous Ovarian Cancer

Epithelial ovarian cancer (EOC) is the ninth most common cause of cancer in Australian women, with an estimated 1500 new diagnoses in Australia in 2015, and remains the seventh most common cause of cancer death in Australian women. High grade serous ovarian cancer (HGSC) is the most common form of ...

Phase

1.94 miles

Learn More »

Pamiparib in Fusion Positive Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy

Ovarian cancer is the deadliest gynaecologic cancer in Western women. Although initially responsive to therapy, drug resistance commonly evolves. Novel mechanisms of drug resistance in ovarian cancer have been identified and include genetic mutations that result in the activation of a drug efflux pump and secondary mutations in BRCA1/2 genes ...

Phase

1.94 miles

Learn More »